SWEDISH ORPHAN/S (SWTUY) Stock Price, News & Analysis

Company Overview

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Key Stats

• Today's Range: $24.38 to $24.38
• 50-Day Range: $24.38 to $24.38
• 52-Week Range: $18.50 to $31.96
• Volume: 200 shs
• Average Volume: 1,665 shs
• Market Capitalization: $6.64 billion
• P/E Ratio: 48.76
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SWTUY Stock Analysis - Frequently Asked Questions

How have SWTUY shares performed this year?

SWEDISH ORPHAN/S's stock was trading at $24.38 at the beginning of the year. Since then, SWTUY stock has increased by 0.0% and is now trading at $24.38.

How do I buy shares of SWEDISH ORPHAN/S?

Shares of SWTUY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Private Households
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SWTUY
• Previous Symbol: NASDAQ:SWTUY
• CIK: N/A
• Web: www.sobi.com
• Phone: 46-0-869-720-00
• Fax: N/A
• Employees: 902
• Year Founded: 2010

Profitability

• EPS (Trailing Twelve Months): $0.50
• Trailing P/E Ratio: 48.76
• Forward P/E Ratio: N/A
• P/E Growth: 1.3
• Net Income: $134.73 million
• Net Margins: 25.75%
• Pretax Margin: N/A
• Return on Equity: 29.63%
• Return on Assets: 18.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $763.19 million
• Price / Sales: 8.71
• Cash Flow: $0.70 per share
• Price / Cash Flow: 34.66
• Book Value: $2.88 per share
• Price / Book: 8.47

Miscellaneous

• Outstanding Shares: 272,508,000
• Free Float: N/A
• Market Cap: $6.64 billion
• Optionable: Not Optionable
• Beta: 1.81